271. 強直性脊椎炎 [臨床試験数:531,薬物数:343(DrugBank:66),標的遺伝子数:41,標的パスウェイ数:141

Searched query = "Ankylosing spondylitis", "Spondylarthritis ankylopoietica"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01330901October 20115/4/2011Ustekinumab for the Treatment of Patients With Active Ankylosing SpondylitisUsTekinumab for the Treatment Of Patients With Active Ankylosing Spondylitis (TOPAS) - a 28-week, Prospective, Open-label, Proof-of-concept StudyAnkylosing SpondylitisDrug: UstekinumabCharite University, Berlin, GermanyNULLCompleted18 YearsN/ABoth22Phase 2Germany
2EUCTR2011-000844-56-DE12/07/201109/06/2011UsTekinumab for the treatment Of Patients with active Ankylosing SpondylitisUsTekinumab for the treatment Of Patients with active Ankylosing Spondylitis (TOPAS) – a 28-week, prospective, open-label, proof-of-concept study - TOPAS Ankylosing spondylitis
MedDRA version: 13.1Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Trade Name: Stelara
Product Name: Ustekinumab
Charité Universitätsmedizin BerlinNULLNot RecruitingFemale: yes
Male: yes
Germany